Buy Voltaren Tablets

After oral administration of tablets, enteric-coated, Diclofenac is completely absorbed from the gut. Although absorption is rapid, its onset may be delayed due to the presence in the tablet enteric coating. The extent of absorption is directly dependent on the dose. When receiving Voltaren tablets during or after the passage of food through the stomach it slows (compared to fasting reception), but the amount of intake of diclofenac is not changed. After the re-admission of the drug pharmacokinetic data are not changed. Under the recommended dosing regimen of the drug accumulation is not observed.

Absorption of rectal suppositories Voltaren started quickly, although its rate of absorption is less in comparison with the same period of ingestion of tablets, enteric-coated. With repeated administration of the drug in the form of suppositories pharmacokinetic parameters are not changed. Subject to compliance with the recommended dosing regimen is not marked accumulation of the drug.

After intramuscular administration of Voltaren 75 mg its absorption begins immediately. The extent of absorption is directly dependent on the dose. pharmacokinetic parameters did not change when the next administration. Subject to the recommended intervals between doses of the drug accumulation is not observed.


About 60% of the dose excreted in the urine as unchanged conjugates glucuronic active substance and in the form of metabolites, most of which are also glucuronic conjugates. The unchanged output of less than 1% diclofenac. The remainder of the dose excreted as metabolites in the bile.

After oral administration of differences in absorption, metabolism or excretion of the drug associated with age, patients were observed. Children diclofenac concentration in plasma when receiving equivalent drug doses (mg / kg) are similar with those of adults.


  • inflammatory and degenerative diseases of the musculoskeletal system: rheumatoid arthritis, ankylosing spondylitis, spondylitis, osteoarthritis, juvenile rheumatoid arthritis (for tablets, enteric-coated, 25 mg and 50 mg or 25 mg rectal suppositories);

  • inflammatory and degenerative forms of rheumatic diseases: rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondylitis (for solution for the / m);

  • diseases of the spine, accompanied by pain syndrome;

  • extra-articular rheumatism of soft tissues;

  • acute gout (for tablets, enteric-coated and solution for the / m);

  • renal colic (for solution for the / m);

  • biliary colic (for solution for the / m);

  • post-traumatic and postoperative pain, accompanied by inflammation and edema;

  • gynecological diseases accompanied by pain and inflammation (eg, primary algomenorrhea, adnexitis);

  • as an adjunct in severe infectious and inflammatory diseases of the ear, nose and throat that occur with severe pain, such as pharyngitis, tonsillitis, otitis media (with the exception of long-acting tablets). The main treatment of the disease is carried out in accordance with conventional principles, including with causal treatment. Isolated fever is not an indication for use of the drug;

  • migraine attacks (suppository);

  • severe migraine attacks (for solution for the / m).